ELVN
Enliven Therapeutics Inc.
NASDAQ: ELVN · HEALTHCARE · BIOTECHNOLOGY
$42.40
-1.35% today
Updated 2026-04-29
Market cap
$2.58B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.83
Dividend yield
—
52W range
$15 – $49
Volume
1.2M
Enliven Therapeutics Inc. (ELVN) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-8.79M | $-8.78M | $-21.88M | $-8.53M | $-19.13M | $-32.08M | $-61.27M | $-73.19M | $-70.30M |
| Capital expenditures | $0.00 | $0.00 | $140000.00 | $461000.00 | $191000.00 | $612000.00 | $149000.00 | $44000.00 | $158000.00 |
| Depreciation | — | — | — | — | — | — | — | — | — |
| Stock-based comp | — | $555000.00 | $899000.00 | $130000.00 | $1.92M | $3.19M | $12.91M | $20.17M | $34.02M |
| Free cash flow | $-8.79M | $-8.78M | $-22.02M | $-8.99M | $-19.32M | $-32.69M | $-61.42M | $-73.24M | $-70.46M |
| Investing cash flow | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | — | — | — | — |